Reuters logo
BRIEF-Neuralstem jumps in premarket after FDA OK's spinal cord injury trial
January 14, 2013 / 1:15 PM / 5 years ago

BRIEF-Neuralstem jumps in premarket after FDA OK's spinal cord injury trial

NEW YORK, Jan 14 (Reuters) - Neuralstem Inc : * Jumps 15.3 percent to $1.43 in premarket after FDA ok’s spinal cord injury trial

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below